Bristol-Myers Squibb Company

BMY

New York Stock Exchange. Currency in USD

71.09 -0.62 ( -0.86% )

Real time prices: September 30

Market Cap.
151.80B
Beta (5Y monthly)
0.42
Price/Earnings
9.29
EPS (TTM)
7.72
Forward Dividend
2.16 (3.07%)
Ex-Dividend Date
Oct 07, 2022
Volume
11.35M
1y Target Est.
81.44
Day's Range
70.98
-
72.11
52 Week's Range
53.22
-
80.59

Historical Summary

Performance
EPS growth
Share Buybacks

About Bristol-Myers Squibb Company

Sector
Healthcare
Industry
Drug Manufacturers-General
Website
https://www.bms.com
Exchange
New York Stock Exchange (XNYS)
Shares Outstanding
2.22B
Employees
32200
Address
430 East 29th Street, New York, NY, United States, 10016
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Latest news

Bristol-Myers Squibb: A Gem In A Period Of Macroeconomic Uncertainties
Bristol-Myers Squibb: A Gem In A Period Of Macroeconomic Uncertainties

The company's medicines received over 10 regulatory approvals in Europe, Japan, and the US in...
By Seeking Alpha - 1 day ago

Dividend Champion, Contender, And Challenger Highlights: Week Of October 2
Dividend Champion, Contender, And Challenger Highlights: Week Of October 2

Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. Click here to see companies...
By Seeking Alpha - 1 day ago

Bristol Myers Squibb (BMY) Stock Moves -0.86%: What You Should Know
Bristol Myers Squibb (BMY) Stock Moves -0.86%: What You Should Know

In the latest trading session, Bristol Myers Squibb (BMY) closed at $71.09, marking a -0.86%...
By Zacks Investment Research - 2 days ago

Bristol Myers Squibb (BMY) Stock Moves -0.49%: What You Should Know
Bristol Myers Squibb (BMY) Stock Moves -0.49%: What You Should Know

In the latest trading session, Bristol Myers Squibb (BMY) closed at $71.71, marking a -0.49%...
By Zacks Investment Research - 3 days ago

Bear Market: 2 Safe Stocks to Buy Right Now
Bear Market: 2 Safe Stocks to Buy Right Now

These businesses might be slightly "boring," but that may just be a good thing in...
By The Motley Fool - 4 days ago

Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?

Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately....
By Zacks Investment Research - 5 days ago

Bristol Myers Squibb (BMY) Stock Moves -0.81%: What You Should Know
Bristol Myers Squibb (BMY) Stock Moves -0.81%: What You Should Know

Bristol Myers Squibb (BMY) closed the most recent trading day at $70.71, moving -0.81% from...
By Zacks Investment Research - 1 week ago

Insiders Selling Nasdaq, Bristol-Myers Squibb And This Consumer Defensive Stock
Insiders Selling Nasdaq, Bristol-Myers Squibb And This Consumer Defensive Stock

The Nasdaq Composite dropped by around 150 points on Thursday. Investors, meanwhile, focused on some...
By Benzinga - 1 week ago